Alcyone Lifesciences demarcates its Hydrocephalus business

Alcyone Lifesciences, a company focused on transforming disease modifying therapies for central nervous system disorders asserted the demarcation of its Hydrocephalus business.

Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation is followed by EU CE Mark and US FDA Clearance of ReFlow Ventricular System for the treatment of hydrocephalus.The FDA 510(k) clearance and EU approval of the ReFlow Ventricular System permits Anuncia to commercialize the innovative technology for treatment of hydrocephalus in the US, and Europe, to provide qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter.

In Hydrocephalus, excess CSF accumulates within the ventricles and surge pressure in the brain therefore leading to fatal situations. CSF shunts are implantable devices inserted by neurosurgeons to treat Hydrocephalus. Although shunts facilitate treatment for many cases, according to The Hydrocephalus Association at least 50 percent of patients implanted with shunts suffer from shunt failures and blockages within two years, requiring repeated revision surgeries.

Edgar D. Jannotta, Jr., Director at Alcyone and Anuncia said “This decision comes after a thorough strategic review by the Board that showed that as independent companies, Alcyone and Anuncia, will be better positioned competitively and enjoy added flexibility to pursue strategic partnerships in their respective markets.”